The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
BACKGROUNDThe objective of this study was to assess the impact of a prostate‐specific antigen (PSA) complete response (PSA‐CR), measured at the end of external‐beam radiotherapy and short‐term hormone therapy, on treatment outcomes.
METHODSThe phase 3 Radiation Therapy Oncology Group 9413 trial, as part of its original protocol, used the assessment of PSA‐CR (ie, PSA ≤0.3 ng/mL) at the end of short‐term...
BACKGROUNDThis study sought to characterize Modern patients with castration‐resistant prostate cancer (CRPC) and identify pretreatment clinical predictors of survival.
METHODSA cohort of men with CRPC with and without metastases (M) treated with secondary hormonal therapy (2eHT) and/or chemotherapy (CT) was identified from the authors' institutional database. Associations of patient and disease characteristics...
BACKGROUNDOptimal management remains unknown following prostate‐specific antigen (PSA) failure when considering comorbidity and PSA kinetics at recurrence. In order to define randomized controlled trials (RCTs) that can address this issue, this study examined factors associated with the risk of death following PSA failure.
METHODSOf 206 men randomized to RT with or without 6 months of androgen suppression...
BACKGROUNDProstate‐specific antigen (PSA) testing is recommended every 6 to 12 months for the first 5 years following radical prostatectomy as a means to detect potential disease recurrence. Despite substantial research on factors affecting treatment decisions, recurrence, and mortality, little is known about whether men receive guideline‐concordant surveillance testing or whether receipt varies by...
BACKGROUNDMany patients with low‐risk prostate cancer (PC) who are diagnosed with Gleason score 6 at biopsy are ultimately found to harbor higher grade PC (Gleason ≥ 7) at radical prostatectomy. This finding increases risk of recurrence and cancer‐specific mortality. Validated clinical tools that are available preoperatively are needed to improve the ability to recognize likelihood of upgrading in...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.